Rising cancer instances across the world boosting requirement of effective treatments and enhanced diagnostic aids such as tyrosine kinase inhibitors in the market. It is a widely accepted treatment owing to the excellent efficacy and improved specificity over the radiotherapy and chemotherapy augmenting the industry growth. Spreading awareness regarding effective usage in varied diseases including lung cancer, renal cancer, breast cancer, and chronic leukemia (CML) aids are propelling industry share. Lung cancer has reported major causes of deaths in several countries. However, government authorities along with the major companies are investing heavily in R&D to address the unmet needs in the overall diagnosis strongly supporting market growth.
Global tyrosine kinase inhibitors market is segmented based on the product as, BCR-ABL TKI, epidermal growth factor receptor (EGFR) TKI, and vascular endothelial growth factor (VEGFR) TKI. On the basis of distributional channel, the global tyrosine kinase inhibitors market is segregated as hospital pharmacies, independent pharmacies, and online pharmacies. Independent pharmacy segment is expected to witness notable gains in the forecast years.
Global tyrosine kinase inhibitors market report covers various regions including North America, Europe, Asia Pacific, and Rest of World. The regional tyrosine kinase inhibitors market is further bifurcated for major countries including U.S., Canada, Germany, UK, France, Italy, China, India, Japan, Brazil, South Africa and others.
Competitive Rivalry
Global tyrosine kinase inhibitors market share consists of several players including Eurofarma Laboratórios, Eisai Co., Johnson & Johnson, Pfizer Inc, Bristol-Myers Squibb Company, Novartis AG, F. Hoffmann-La Roche Ltd., Bayer AG, AstraZeneca Plc, and Boehringer Ingelheim International.
The Tyrosine Kinase Inhibitors Market has been segmented as below:
Tyrosine Kinase Inhibitors Market, By Product
Tyrosine Kinase Inhibitors Market, By Distribution Channel
Tyrosine Kinase Inhibitors Market, By Region
The report covers:
Report scope:
The global tyrosine kinase inhibitors market report covers detailed study with the underlying influencing factors for the variations in the industry growth trends.
The report scope includes market analysis on regional as well as country level. The report also provides competitive landscape covering company market shares with detailed profiling for major revenue contributing companies.
The report covers a detailed competitive outlook including the market share and company profiles of the key participants operating in the global market. Key players profiled in the report include Eurofarma Laboratórios, Eisai Co., Johnson & Johnson, Pfizer Inc, Bristol-Myers Squibb Company, Novartis AG, F. Hoffmann-La Roche Ltd., Bayer AG, AstraZeneca Plc, and Boehringer Ingelheim International.
Reasons to Buy this Report:
Customization:
Customized report as per the requirement can be offered with appropriate recommendations
Below are our new reports:
Traumatic Brain Injury Therapeutics Market
1. Introduction
1.1. Key Points
1.2. Report Description
1.3. Markets Covered
1.4. Stakeholders
2. Research Methodology
2.1. Research Scope
2.2. Research Methodology
2.2.1. Market Research Process
2.2.2. Research Methodology
2.2.2.1. Secondary Research
2.2.2.2. Primary Research
2.2.2.3. Models for Estimation
2.3. Market Size Estimation
2.3.1. Bottom-Up Approach
2.3.2. Top-Down Approach
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Drivers
4.2.1. Increasing number of cancer patients worldwide
4.2.2. Rising healthcare expenditures from the major countries
4.2.3. Driver 3
4.3. Restraints
4.3.1. Restraint 1
4.3.2. Restraint 2
4.4. Opportunities
4.4.1. Opportunity 1
4.4.2. Opportunity 2
4.5. Challenges
4.5.1. Challenge 1
4.5.2. Challenge 2
5. Tyrosine Kinase Inhibitors Market, By Product
5.1. Key Points
5.2. BCR-ABL TKI
5.3. Epidermal Growth Factor Receptor (EGFR) TKI
5.4. Vascular Endothelial Growth Factor (VEGFR) TKI
6. Tyrosine Kinase Inhibitors Market, By Distribution Channel
6.1. Key Points
6.2. Hospital Pharmacies
6.3. Independent Pharmacies
6.4. Online Pharmacies
7. Competitive Landscape
7.1. Introduction
7.2. Recent Developments
7.2.1. Mergers & Acquisitions
7.2.2. New Product Developments
7.2.3. Portfolio/Production Capacity Expansions
7.2.4. Joint Ventures, Collaborations, Partnerships & Agreements
7.2.5. Others
8. Company Profile
8.1. Eurofarma LaboratĂ³rios
8.1.1. Company Overview
8.1.2. Product/Service Landscape
8.1.3. Financial Overview
8.1.4. Recent Developments
8.2. Eisai Co
8.2.1. Company Overview
8.2.2. Product/Service Landscape
8.2.3. Financial Overview
8.2.4. Recent Developments
8.3. Johnson & Johnson
8.3.1. Company Overview
8.3.2. Product/Service Landscape
8.3.3. Financial Overview
8.3.4. Recent Developments
8.4. Pfizer Inc
8.4.1. Company Overview
8.4.2. Product/Service Landscape
8.4.3. Financial Overview
8.4.4. Recent Developments
8.5. Bristol-Myers Squibb Company
8.5.1. Company Overview
8.5.2. Product/Service Landscape
8.5.3. Financial Overview
8.5.4. Recent Developments
8.6. Novartis AG
8.6.1. Company Overview
8.6.2. Product/Service Landscape
8.6.3. Financial Overview
8.6.4. Recent Developments
8.7. F. Hoffmann-La Roche Ltd
8.7.1. Company Overview
8.7.2. Product/Service Landscape
8.7.3. Financial Overview
8.7.4. Recent Developments
8.8. Bayer AG
8.8.1. Company Overview
8.8.2. Product/Service Landscape
8.8.3. Financial Overview
8.8.4. Recent Developments
8.9. AstraZeneca Plc
8.9.1. Company Overview
8.9.2. Product/Service Landscape
8.9.3. Financial Overview
8.9.4. Recent Developments
8.10. Boehringer Ingelheim International
8.10.1. Company Overview
8.10.2. Product/Service Landscape
8.10.3. Financial Overview
8.10.4. Recent Developments
The Tyrosine Kinase Inhibitors Market has been segmented as below:
Tyrosine Kinase Inhibitors Market, By Product
Tyrosine Kinase Inhibitors Market, By Distribution Channel
Tyrosine Kinase Inhibitors Market, By Region
